Hiroyuki Hounoki

Hiroyuki Hounoki

Auto-generated profile, based on publicly available information

Hiroyuki Hounoki

First Department of Internal Medicine, University of Toyama, Toyama, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
KHKazuya Hirata
Kazuya Hirata
HTHirofumi Taki
Hirofumi Taki
KSKouichiro Shinoda
Kouichiro Shinoda
HHHiroyuki Hounoki
Hiroyuki Hounoki
TMTatsuro Miyahara
Tatsuro Miyahara
ESEiji Sugiyama
Eiji Sugiyama
Whether tumor progression locus 2 (Tpl2)/cancer Osaka thyroid (Cot) protein kinase participates in osteoclastogenesis from receptor activator of nuclear factor-kappaB ligand (RANKL)-stimulated monocytes/macrophages remains elusive. To clarify this, a selective and potent inhibitor of Tpl2, 1,7-naphtyridine-3-carbonitrile, was used. When RAW264.7 cells were stimulated with RANKL, Tpl2 was found to be activated. Under this condition, the Tpl2 inhibitor suppressed osteoclastogenesis in a dose-dependent manner. This was due to the blockade of the phosphorylation of mitogen activated protein kinase/ERK kinase (MEK) and extracellular signal-regulated kinase (ERK), but not c-Jun N-terminal kinase (JNK) or p38, concomitant with the down-regulation of the c-Fos and nuclear factor of activated T cells (NFAT)c1 genes. A long period of RANKL-stimulated cell exposure to the inhibitor suppressed osteoclastogenesis as assessed by tartrate-resistant acid phosphatase (TRAP) staining and pit formation on dentin slices. Almost identical results were obtained with macrophage colony-stimulating factor (M-CSF) and RANKL-stimulated bone marrow cells. These findings suggest the possibility that Tpl2 plays a pivotal role in osteoclastogenesis and thus that its inhibitor is useful for investigating the differentiation of monocytes/macrophages to osteoclasts after treatment with RANKL or other stimuli.

12 December 2023 in Case Reports in Rheumatology
Verified
Journal Article
Open access
PDF file
HHHiroyuki Hounoki
Hiroyuki Hounoki
TOTakafumi Onose
Takafumi Onose
MYMiho Yamazaki
Miho Yamazaki
RARyoko Asano
Ryoko Asano
SYSatoshi Yamaguchi
Satoshi Yamaguchi
KHKenichi Hirabayashi
Kenichi Hirabayashi
Small cell neuroendocrine carcinoma is rare among urinary bladder cancer types, and to date, there are no case reports of concurrent antitranscriptional intermediary factor 1-γantibody-positive dermatomyositis. We describe the case of a 69-year-old Japanese man who presented with elevated creatine kinase levels and haematuria on medical examination. Approximately one month later, he developed dysphagia. Laryngoscopy confirmed laryngeal dysfunction. He also presented with muscle weakness and a skin rash. Magnetic resonance imaging of the upper extremities suggested bilateral brachial muscle myositis. He was diagnosed as having dermatomyositis and was later found to be positive for antitranscriptional intermediary factor 1-γ antibody. Computed tomography revealed an intravesical space-occupying lesion and right iliac lymphadenopathy, suggesting urinary bladder cancer. The patient was admitted to our hospital for treatment. Urinary bladder biopsy confirmed small cell neuroendocrine carcinoma because tumour cells were positive for synaptophysin, CD56, and chromogranin A. Thus, the patient was diagnosed as having an antitranscriptional intermediary factor 1-γantibody-positive dermatomyositis concomitant with urinary bladder small cell neuroendocrine carcinoma. The patient was treated with glucocorticoid and intravenous immune globulin therapy for dermatomyositis. Radiotherapy was selected for the carcinoma. Although muscle weakness and skin symptoms improved with treatment, dysphagia persisted. Furthermore, expression of the transcriptional intermediary factor 1-γ protein in tumour cells was also confirmed by immunohistochemistry, but the significance is unknown. It should be noted that antitranscriptional intermediary factor 1-γantibody-positive dermatomyositis can occur concomitantly with such a rare malignancy.

8 July 2026 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
RARyoko Asano
Ryoko Asano
SYSatoshi Yamaguchi
Satoshi Yamaguchi
KSKoichiro Shinoda
Koichiro Shinoda
HHHiroyuki Hounoki
Hiroyuki Hounoki
TKToshiki Kido
Toshiki Kido
MKMasaru Kato
Masaru Kato

7 August 2026 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
EMEzaki Masayoshi
Ezaki Masayoshi
KNKato Noriko
Kato Noriko
KNKentaro Nagaoka
Kentaro Nagaoka
MYMurai Yushi
Murai Yushi
SKSugie Kazushige
Sugie Kazushige
YYYoshihiro Yamamoto
Yoshihiro Yamamoto